Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Timothy Kross who wrote (115)	7/11/1998 3:01:00 PM
From: Arthur Radley	Read Replies (2) \| Respond to of 626

Thanks Tim for the news. I will look forward to getting my copy of the report.

To: Timothy Kross who wrote (115)	7/12/1998 1:20:00 AM
From: Lel H	Read Replies (1) \| Respond to of 626

Hello everyone. I'm new to this board (note the "Trial Member" designation), but I'm not new to TTNP. I got in a few months ago in anticipation of the Iloperidone phase III announcement. Tim, your calculation of the potential profits from Iloperidone certainly makes the Japanese market seem lucrative. TTNP would have to capture over 25% of the North American market to generate that kind of revenue, based on the agreement with Novartis. Does retaining Japanese marketing rights mean that Novartis gets no cut, despite the fact that it's shelling out >$100 million to fund the phase III trial? Best wishes, Lel